Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Alfred E Tiefenbacher GmbH.

  • Webinars & Exhibitions

PharmaCompass
Tiefenbacher Group
Alfred E Tiefenbacher GmbH
Germany Flag
Country
Country
Germany
Address
Address
Van-der-Smissen-Strasse 1, 22767 Hamburg
Telephone
Telephone
+49 404418090
Client Website
Website
Twitter
Twitter
Contact Info
Others

Details:

Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.


Lead Product(s): Abiraterone Acetate,Prednisolone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 17, 2022

Tiefenbacher Compnay Banner

Iran Expo

Not Confirmed

envelop Contact Supplier

Details:

Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.


Lead Product(s): Teriflunomide

Therapeutic Area: Immunology Product Name: Teriflunomide-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

Tiefenbacher Compnay Banner

Iran Expo

Not Confirmed

envelop Contact Supplier

Details:

Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.


Lead Product(s): Lacosamide

Therapeutic Area: Neurology Product Name: Lacosamide-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 22, 2022

Tiefenbacher Compnay Banner

Iran Expo

Not Confirmed

envelop Contact Supplier

Details:

The partnership aims to develop and commercialize products in the intersection between traditional drug-based medicine and digital therapeutics. Another novelty is to dispense the drugs as pellets instead of pills or capsules, making them easier to consume.


Lead Product(s): Undisclosed

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: OnDosis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Expanded Collaboration September 26, 2021

Tiefenbacher Compnay Banner

Iran Expo

Not Confirmed

envelop Contact Supplier

Details:

Bilastine is an innovative anti-allergy medicine improving the life of patients suffering from allergic symptoms also a second-generation antihistamine product helps to relieve nasal and non-nasal symptoms of seasonal rhinitis as well as urticaria caused symptoms.


Lead Product(s): Bilastine

Therapeutic Area: Immunology Product Name: Bilastine-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 20, 2021

Tiefenbacher Compnay Banner

Iran Expo

Not Confirmed

envelop Contact Supplier

Details:

Teriflunomide is a novel disease-modifying agent,primarily an inhibitor of dihydroorotate-dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells.


Lead Product(s): Teriflunomide

Therapeutic Area: Immunology Product Name: Teriflunomide-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 23, 2021

Tiefenbacher Compnay Banner

Iran Expo

Not Confirmed

envelop Contact Supplier

Details:

Posaconazole Delayed-Release Tablets, 100 mg, are the generic equivalent of Noxafil Delayed-Release Tablets, 100 mg, of Merck Sharp & Dohme Corp, and are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are severely immunocompromised.


Lead Product(s): Posaconazole

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Lupin Ltd

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 17, 2021

Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY